^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    sabestomig (AZD7789)

    i
    Associations
    News

    Trials

    Company:
    AstraZeneca
    Drug class:
    PD1 inhibitor, TIM-3 inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (GEMINI-Gastric) (NCT05702229)
    Phase 2
    AstraZeneca
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    01/16/2023
    Primary completion :
    01/30/2026
    Completion :
    01/28/2027
    CLDN18
    |
    5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • sonesitatug vedotin (AZD0901) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • sabestomig (AZD7789)
    Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung04) (NCT04612751)
    Phase 1
    AstraZeneca
    Recruiting
    Last update posted :
    02/05/2025
    Initiation :
    02/02/2021
    Primary completion :
    01/30/2026
    Completion :
    01/30/2026
    EGFR • PD-L1 • ALK
    |
    PD-L1 expression
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • Datroway (datopotamab deruxtecan) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • sabestomig (AZD7789)
    PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC (MST01-AZN-05) (NCT06366451)
    Phase 1
    Presage Biosciences
    Recruiting
    Last update posted :
    01/20/2025
    Initiation :
    05/22/2024
    Primary completion :
    02/01/2025
    Completion :
    04/01/2025
    TMB • MSI
    |
    Keytruda (pembrolizumab) • tilatamig samrotecan (AZD9592) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • sabestomig (AZD7789)
    Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies (NCT04541108)
    Phase 1
    Presage Biosciences
    Recruiting
    Last update posted :
    04/18/2024
    Initiation :
    07/26/2021
    Primary completion :
    12/01/2031
    Completion :
    12/01/2031
    CD8 • TNFA • CD163 • CD4 • NCAM1 • CASP3 • CD68 • GZMB • CD86
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • carboplatin • paclitaxel • 5-fluorouracil • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • BMS-986299 • MK-0482 • MK-4830 • dazostinag (TAK-676) • sabestomig (AZD7789)